Prognostic Indicators for Radiation-induced Breast Fibrosis
Breast CancerTo study the inflammatory response during and after radiotherapy, especially by measuring the concentration of an enzyme called autotaxin and its product LPA in the blood plasma.
null
Conditions de participation
-
Sexe:
FEMALE -
Âges admissibles:
40 and up
Critères de participation
Inclusion Criteria:
1. Female participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf
2. Age 40 and above.
3. Treatment with breast conserving surgery.
4. Intended adjuvant whole breast radiotherapy dose to a dose of 40-42.5 Gy in 15-16 fractions.
5. Luminal A subtype as determined by clinipathologic factors (ER/PR positive, Her-2 negative, low Ki-67 or low OncotypeDx recurrence score
Exclusion Criteria:
1. Women who have smoked within the last 5 years
2. Patients requiring adjuvant chemotherapy.
3. Requirement for regional nodal radiotherapy.
4. Requirement for tumour bed boost.
5. Breast implants
6. Patients to be treated with partial breast irradiation.
7. Uncontrolled intercurrent illness or active infection.
8. Patients who have previously received chemotherapy.
9. Patients who have previously received chemotherapy.
Lieu de l'étude
Cross Cancer Institute
Cross Cancer InstituteEdmonton, Alberta
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- AHS Cancer Control Alberta
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT05031065